IL-2Rbeta and IL-15 Agonist Combination for Cancer Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in identifying effective combination therapies that can enhance the immune system's ability to target cancer cells without developing drug resistance.
Innovation Solution
Administering a long-acting IL-2Rβ-selective agonist in combination with a long-acting IL-15 agonist to activate immune cells, thereby enhancing the immune system's response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with IL-2Rβ-selective agonist and IL-15 agonist is administered, then immune system activation and anti-tumor efficacy are improved, but treatment complexity and difficulty of identifying effective combinations increase
Solution Approach 1:
The patent combines two immunotherapeutic agents (IL-2Rβ-selective agonist and IL-15 agonist) into a single combination therapy regimen. This merging of treatments creates a synergistic effect that enhances immune system activation and anti-tumor efficacy beyond what either agent could achieve alone, directly addressing the contradiction by improving reliability through combination while managing the inherent complexity through systematic evaluation protocols
Solution Approach 2:
The combination therapy regimen is designed to simultaneously target multiple immune pathways (IL-2Rβ signaling and IL-15 signaling) with a single treatment protocol. This multi-functional approach allows the therapy to activate different aspects of the immune system (T-cell proliferation, memory T-cell formation, NK cell activation) concurrently, improving overall anti-tumor efficacy while providing a unified treatment framework that manages complexity
2Duration of action of moving object
If long-acting IL-2Rβ-selective agonist and long-acting IL-15 agonist are administered, then duration of immune activation is improved, but identification of beneficial combination becomes more difficult
Solution Approach 1:
The patent employs preliminary in vitro assays and in vivo murine tumor models to evaluate the combination therapy before clinical application. These preliminary studies systematically assess the interaction between long-acting IL-2Rβ-selective agonists and long-acting IL-15 agonists, identifying beneficial combinations and optimal dosing regimens in advance. This preliminary action reduces the difficulty of detecting and measuring effective combinations in later clinical stages while maintaining prolonged immune activation
Solution Approach 2:
The development process incorporates feedback loops where results from in vitro studies inform in vivo model design, and outcomes from murine tumor models guide clinical trial protocols. This systematic feedback mechanism allows researchers to iteratively optimize the combination of long-acting agents, improving both the duration of immune activation and the ability to identify beneficial combinations through accumulated experimental evidence
Data Source
AI summary
In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2Rβ-selective agonist and the long-acting, IL-15 moiety.